Loading...
Market
Outcome of Halozyme's Proposed Acquisition of Evotec by End of 2025?
3
Resolution / Starting Odds
Successful acquisition at €11 per share • 25%
Acquisition at a different price • 25%
Acquisition fails • 25%
Acquisition postponed • 25%
Official announcements from Halozyme, Evotec, or financial news outlets
Story
Halozyme Proposes €2 Billion Takeover of Evotec at €11 Per Share, 27% Premium
Nov 14, 2024, 09:30 PM
Halozyme Therapeutics is reportedly exploring a takeover of the German drugmaker Evotec, with a proposed acquisition valued at approximately €2 billion ($2.1 billion). The offer includes a cash payment of €11 per share, representing a 27% premium over Evotec's last closing price. This potential acquisition aims to enhance Halozyme's drug discovery and development portfolio. The interest from Halozyme comes as Evotec has garnered attention in the biotechnology sector, with various reports confirming the ongoing discussions between the two companies.
View original story
Similar markets
Takeover completed • 25%
Takeover offer made but not completed • 25%
No takeover offer made • 25%
Triton sells its stake • 25%
Increase by 0-5% • 25%
Increase by 5-10% • 25%
Increase by 10-15% • 25%
Increase by more than 15% • 25%
Yes • 50%
No • 50%
Outperforms DAX by more than 10% • 25%
Outperforms DAX by up to 10% • 25%
Performs similar to DAX • 25%
Underperforms DAX • 25%
Yes • 50%
No • 50%
Majority of board changes • 25%
Some board changes • 25%
No board changes • 25%
Board expansion • 25%
